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1. Introduction 
Coeliac disease (CD) is a form of gluten intolerance in which the small bowel is damaged by 
proteins present in wheat, rye, barley and some varieties of oats (Mäki & Collin, 1997). . 
These proteins cause severe damage to the duodenum and jejunum (villous atrophy) and 
can produce a variety of symptoms such as abdominal pain and cramping, bloating 
diarrhoea, nausea and lethargy. 
The discovery of the disease by Dicke led to treatment by means of a gluten-free diet, which 
needs to be maintained for the rest of life (Dicke et al, 1953). If left untreated, severe 
malabsorption causes the loss of vital nutrients, resulting in conditions such as osteoporosis. 
In addition, anaemia and long-term immune and autoimmune mechanisms can induce 
lymphomas (van Heel & West, 2006) . 
Diagnosis thus needs to be effected early in life and screening tests are available that are 
based on antibodies to tissue transglutaminase. If positive, biopsies are necessary to confirm 
the diagnosis of CD (Sollid, 2002). 
In people of European descent about one in 100 people suffer from CD, but the disease is 
considerably under-diagnosed. This is partly because, over the last two decades, the 
symptoms have changed and become more covert (van Heel & West, 2006). Hence, it is vital 
that the correct diagnosis be made, taking advantage of serology and endoscopic biopsy, 
and if positive, a gluten free diet commenced. In addition, we recommend that enzyme 
supplementation be utilized in order to hasten repair to tissue and help to begin a greatly 
improved lifestyle (Cornell & Stelmasiak, 2007). 
The background to our work on enzyme therapy began with studies of etiology of CD and 
were essentially of a biochemical nature. Although treatment with a gluten-free diet had 
been hailed as a major breakthrough in patient management, the disease was still poorly 
understood and further studies were considered absolutely necessary. Like other studies of 
CD, they were based on showing that the proteins in the gluten fraction of wheat were the 
causative agents (Anderson et al, 1952). Later, Frazer et al, (1959) showed that a peptic-
tryptic digest of gluten was still toxic to patients with CD and obtained an indication that 
this toxicity was abolished by further treatment of the digest with an extract of hog mucosa, 
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suggesting an enzyme deficiency was the cause of CD. Bronstein et al (1966) showed the 
peptic-tryptic-pancreatinic digests of the lower molecular weight group of proteins, called 
gliadin, were toxic in vivo. The following experiments were conducted to investigate the 
toxic factors present. 
Fractionation of such a gliadin digest by ion exchange showed that it contained a fraction 
(Fraction 9) that was incompletely digested by small intestinal mucosa from children with 
coeliac disease in remission (Cornell & Townley, 1973). Undigested residues showed up 
after electrophoresis of the mucosal digests. 
Small intestinal mucosa from children with active coeliac disease was cultured in the 
presence of each fraction of the gliadin digest. Electron microscopy was used to observe the 
changes to the tissue. Fraction 9 was again seen as being different from the other fractions in 
that it prevented recovery of the tissue and thus was shown to be highly toxic (Townley et 
al.,1973). 
Feeding tests using the xylose tolerance method in children showed that Fraction 9 was the 
only fraction to cause a reduction in urinary xylose excretion, thus confirming its toxicity in 
vivo (Cornell&Townley, 1974). 
Collaboration with Anderson and Rolles (Cornell & Rolles, 1978) showed that there was a 
partial enzyme deficiency in a number of the first degree relatives of the coeliac probands, 
and helped explain the wide-range of symptoms observed in coeliac disease. 
These studies confirmed that residues of undigested peptides were higher from coeliac 
patients in remission than from controls.  
Further work was then focused on the structures of the peptides present in Fraction 9 and 
the types of mechanisms that might operate in CD. Further collaboration in regard to other 
assays of toxicity was of the utmost importance as was the introduction of tests on synthetic 
peptides.  
2. The structures of the toxic peptides 
A considerable amount of research has been necessary to define the toxic peptides present in 
such a complex mixture as a gliadin digest. The basis for these experiments was finding that 
the toxicity of gliadin, in the form of a low molecular weight digest (approximately 1500 
Daltons average) was concentrated in Fraction 9 (Cornell & Townley, 1973). Hence it was 
decided to further fractionate Fraction 9 and perform amino acid analysis on the sub-
fractions. Alongside these analytical experiments, it was, of course necessary to evaluate the 
in vitro toxicity of the various sub-fractions. This was achieved by the use of a screening 
assay based on the observation that rat liver lysosomes were disrupted by a peptic-tryptic 
digest of gluten (Dolly & Fottrell, 1969). Using an assay based on lysosome disruption it was 
confirmed that Fraction 9 was the most toxic of the ion-exchange fractions obtained and this 
herewith gave confidence in the value of the assay as a screening test for toxicity (Cornell & 
Townley, 1973b). 
The justification for the use of the rat liver lysosome assay mainly came from the work of 
Riecken et al.(1966), who showed that human lysosomes lost their integrity in patients with 
active coeliac disease, but this integrity was regained on a gluten-free diet. The value of 
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prednisolone in promoting recovery of mucosa in coeliac disease is known to be due to 
stabilization of lysosomal membranes (Weissman, 1966). 
Fraction 9 was not only shown to be the most active fraction, but peptides remaining after 
digestion of Fraction 9 with remission coeliac mucosa still had an appreciable effect of 
lysosomal membranes, whereas those remaining after digestion of Fraction 9 with normal 
intestinal mucosa had only little effect (Cornell & Townley,1973b). 
The mucosal digestion experiments were repeated with an extract of porcine intestinal 
mucosa in comparison with remission coeliac mucosa and normal mucosa. Protection of the 
lysosomes was high with the porcine and normal human mucosal extracts but was low with 
remission coeliac mucosal extract (Cornell& Stelmasiak, 2004). 
These experiments showed the value of lysosomes in our understanding of an enzyme 
deficiency in coeliac disease. Most importantly, they have opened the way for enzyme 
therapy, which began with tests on animal intestinal extracts. Lysosomal assays thus form 
the basis of our assays for detoxification of gliadin. 
The rat liver lysosome assay was employed in two different ways: 
- The first way was to evaluate the toxicity of fractions of a gliadin digest and the 
synthetic peptides corresponding to the A-gliadin structure. Confirmation of the in-vitro 
toxicity of the latter in a chick assay (Mothes et al., 1985) could then be undertaken. For 
this purpose, the toxicity of each of the fractions was calculated from  





where T = toxicity 
 Z = absorbance at 410nm after dilution with buffer and 
 A = absorbance at 410nm after incubation at 37°C for 1.5 hours and then dilution 
with buffer. 
Toxicity is thus a percentage reduction in absorbance caused by disruption of the lysosomes 
and has been shown to be highest in the case of Fraction 9, compared to all the other 
fractions of the gliadin digest (Cornell & Townley, 1973b). 
- The second way in which the assay was used was to evaluate the percentage protection 
offered by various animal and human mucosal extracts, plant extracts and commercial 
enzymes. Pre-incubation of the gliadin digest with enzyme solution, followed by 
incubation with lysosomes and dilution with buffer was necessary. Absorbance at 
410nm of this mixture (E) was then used to calculate P (%) as follows: 




  × 100 
P can also be calculated from 




 × 100 
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where TE = Toxicity after pre-incubation with enzyme. 
Mucosal digestion was carried out by homogenizing tissue in PBS (30mg/mL) followed by 
filtration. The assay normally used 0.20ml of the filtrate per tube, 0.10ml of gliadin digest 
(50mg/mL) and 0.10ml of a rat liver lysosome suspension. This latter suspension was of 
such concentration that 0.10ml when diluted with PBS gave an absorbance reading of 0.9-1.0 
at 410mm (Cornell & Townley, 1973b). 
The starting point for all subsequent studies was to determine the composition of the toxic 
peptides present in Fraction 9. This was achieved by HPLC of Fraction 9 on ODS Hypersil 
followed by amino acid analysis of the sub-fractions (Cornell et al.1992). The most active 
fractions, as determined by the lysosomal screening assay, were then subjected to amino 
acid sequencing. This led to the identification and amino acid sequence of two peptides – 
one corresponding to residues 5-20 of A-gliadin from wheat (Fraction 13) and the other 
(Fraction 20) corresponding to residues 75-86 of A-gliadin, the A-gliadin sequence having 
been determined by Kasarda et al.(1994). 
Sub-fraction 13 was shown to contain two peptides of similar amino acid composition and 
indicating about 16 residues in each. Both were close in composition to the peptide 5-20 of 
A-gliadin, which contains the PSQQ and QQQP motifs, seen to be important to toxicity by 
De Ritis et al. (1988).  
Sub-fraction 20-1 (rechromatographed Sub-fraction 20) was shown to be identical to 
residues 75-86 of A-gliadin and specific amino acid deletions were useful in showing that 
toxicity in the chick assay was lost below the size of the octapeptide 77-84 (Cornell & 
Mothes,1993). Peptide 75-84 still retained toxicity. Peptides within the sequence 75-86 
appear to be immunogenic peptides, as shown by their ability to cause the release of 
gamma-interferon from red blood cells of patients with CD (Cornell et al., 1994). 
 Sealy-Voyksner et al (2010) have identified several peptides in gluten digests that are 
relevant to the immunological response in patients with CD. Some of these correspond to 
segments of α – and ß-gliadins, and were close matches to those in previous studies on A-
gliadin (Mc Lachlan et al.2002). Importantly, one of these peptides contained the PQQPYP 
motif found in the active peptide 75-86 of A-gliadin (Cornell & Mothes, 1993).  
The work of De Ritis et al (1988), was an important finding as it enabled McLachlan et al 
(2002) to use a proteomics approach to investigate common sequences in wheat, rye and 
barley – the most toxic cereals to patients with CD – and compare them with oats  (having 
questionable toxicity in CD) and maize and rice (non-toxic cereals). They found that QQQP 
was present in a number of sequences in wheat, but QQQPS was also found in the non-toxic 
cereals, maize and rice. This led to the conclusion that the flanking amino acids were also 
important and extended motifs needed to be examined. When this was done it turned out 
that an extended motif common to wheat, rye and barley was QQQPFP. A shorter motif, 
QQQPF was also present in oats and may be present in the cultivars of this cereal which 
have been shown to have activity in some ‘in-vitro’ assays (Silano et al., 2006). 
Regarding the PSQQ motif, proposed by De Ritis et al. (1988) the relevant extended motifs 
were FPSQQ, PSQQP, PFPSQQ and FPSQQP, but these were associated only with wheat 
and barley, not rye. 
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The proteomics approach opened the way for looking at other motifs which may be 
associated with CD toxicity. Mention has already been made of HPLC of Fraction 9 and 
amino acid analysis of the fractions. These experiments showed that there were two sub-
fractions which were toxic to rat liver lysosomes and that amino acid analysis and amino 
acid sequence determinations pointed to structures corresponding to residues 5-20 and 75-
86 of A-gliadin. The latter peptide proved to be the most abundant one of sequence 
RPQQPYPQPQPQ. It was thought that the key sequence in this peptide could be a four 
amino acid motif like QQPY, since the proteomic studies indicated that wheat, rye and 
barley all contained the extended motifs PQQPY and QQPYP which are both present in 
peptide 75-86(McLachlan et.al.,2002). Other searches had shown that peptide 31-49 of A-
gliadin (LGQQQPFPPQQPYPQPQPF) was toxic “in vivo” to patients with CD (Sturgess et 
al.1994). It can be seen that the extended (5 amino acid) sequences are also both present in 
this peptide. Fetal chick assays were also carried out on a series of peptides related to 
peptide 75-86(Cornell & Mothes, 1993). These assays showed that all peptides in this region 
had appreciable toxicity except peptide 76-86 with an N-terminal proline residue. 
Regarding peptide 5-20 (VPQLQPQNPSQQQPQE), it is seen that not only the PSQQ motif, 
but the QQQP motif, is also present. The extended motifs PSQQQ, NPSQQQ and PSQQQ 
are found only in wheat. Again, it was found that searches for the four amino acid motif 
QPYP, resulted in matches for wheat, rye, barley, oats and the non-toxic rice indicating the 
need for using an extended motif. 
The significance of this work only became apparent when the mucosal digestion studies of 
synthetic peptides and fetal chick assays were carried out. The use of the latter assay in 
connection with synthetic peptides prepared with selective amino acid deletions, showed 
that peptide 11-19 was the most active peptide within the sequence of 5-20. It was 
considerably more active than peptide 8-19, reported by Kocna et al. (1991), who used the 
same assay. The octapeptide 12-19, which contains motifs PSQQ and QQQP in overlapping 
sequence, was still toxic in the assay. This reinforced the view that sequences of eight-amino 
acids are large enough to retain toxicity, whereas the hexapeptide 13-18 is not (Cornell & 
Mothes, 1993).  
Peptide 11-19 gave higher amounts of residues after digestion with remission coeliac 
mucosa than were obtained with normal mucosa. Moreover, these residues still retained the 
serine residue, presumably associated the PSQQ motif, because the amino acid composition 
of the residues matched the octapeptide sequence 12-19, QNPSQQQPQ (Cornell & Rivett, 
1995). It is interesting that peptide 206-217, has been shown to be toxic in vivo (Mantzaris & 
Jewell, 1991). Its sequence of LGQGSFRPSQQN contains the PSQQ motif, which may be a 
problem with digestion by coeliac mucosa.  
Mucosal digestion and amino acid analysis of residues from peptide 75-86 were also very 
informative (Cornell, 1998). Again, like peptide 11-19, digestion with remission coeliac 
mucosa was not complete and residues corresponding to octapeptides were obtained. These 
residues seemed to correspond to peptide 77-84 (QQPYPQPQ) which was shown to be toxic 
in the fetal chick assay. Such residues also contain the QQPYP extended motif, suggesting 
that an enzyme deficiency in remission coeliac mucosa is the reason why these undigested 
residues remain and also why the extended motifs present in residues 12-19, QNPSQQQPQ 
(from peptide 11-19) and 77-84, QQPYPQPQ (from peptide 75-86) both contain the extended 
amino acid sequences corresponding to the three most toxic cereal proteins. 
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With regard to the activity of other peptides of A-gliadin, Vader et al.,(2002) have shown 
that gluten-specific T-cell responses in HLA-DQ2 positive adult coeliac patients are directed 
at multiple peptides of gliadin and glutenin. An interesting example is peptide 56-68 of A-
gliadin (LQLQPFPQPQPY). By the criterion of activation of coeliac intestinalCD4+ T-clones 
(Halstensen et al., 1993), it is the dominant epitope, yet it is not able to cause damage in vitro. 
Another two examples are the A-gliadin peptides 31-43 and 31-49. The former peptide does 
not activate coeliac intestinal CD4+ T-clones (McAdam & Sollid, 2000). Peptide 31-49 
(LGQQQPFPPQQPYPQPQPF) which is toxic in vivo (Sturgess et al., 1994) has the De Ritis 
motif QQQP and the tyrosine motifs QQPY and QPYP, both of which are associated with 
coeliac-toxic cereals (McLachlan et al., 2002). However, peptide 31-43 has only the QQQP 
and QQPY but not QPYP, so the latter may have great importance in toxicity. Like peptide 
31-49, the 33-mer peptide of alpha-2 gliadin (Shan et al.,2002) also has the PYPQ motif.  
Toxic action seen on fetal rat jejunum, but not on mature jejunum, is consistent with 
development of protective enzymes or immune mechanisms. Experiments in vitro 
production of interferon indicated that the serine-containing peptides, like peptide 11-19 of 
A-gliadin, were weakly immunogenic (but potent in their cytotoxicity) compared with the 
tyrosine-containing peptides like peptide 75-86 of A-gliadin (Cornell & Wills-Johnson, 2001). 
Other workers (McAdam & Sollid, 2000; Shan et al., 2002) have reported immunogenic 
peptides containing tyrosine. Peptides 57-73 of A-gliadin and 57-89 of α-2 gliadin do not 
have PSQQ or QQQP motifs, but the latter has the QPYP motif common to all three coeliac 
toxic cereals (McLachlan et al., 2002). 
Secondary structural differences in the peptides 11-19 and 75-86 have been suggested by 
molecular modelling. This work indicates that peptide 11-19 favours an  α-helical structure, 
whereas peptide 75-86 has high  β-turn content  Similarly, peptides in an avenin from oats, 
which also appear to be highly immunoreactive, have been shown to have a high β-turn 
content using circular dichroism(Alfonso et al.,1998). 
3. Etiology of coeliac disease 
Studies of possible enzyme deficiency have been rewarding, in that, using different 
techniques, all the results have pointed to two particular peptides from A-gliadin that seem 
to have different modes of action in regard to their toxicity, yet both are incompletely 
digested by remission coeliac mucosa (Cornell & Rivett,1995; Cornell,1998). 
An enzyme deficiency has been indicated not only from studies of native gliadin but also 
from studies using synthetic peptides. At this point it would be of benefit to readers to list 
the findings which support an enzyme deficiency.  
a. One fraction of a gliadin digest (Fraction 9) was incompletely digested by small 
intestinal mucosa from patients with CD in remission. This fraction was completely 
digested by small intestinal mucosa from normal individuals as were all the other 
fractions of the digest by mucosa from normal and those with CD (Cornell & Townley, 
1973). 
b. Cultures of small intestinal mucosa from patients with active CD improved after 24 
hours in media containing fractions other than Fraction 9 or in the absence of gliadin. 
This was in complete contrast to tissue from patients in the presence of Fraction 9. 
Tissue from normal individuals was not damaged, except to a small extent with 
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Fraction 9. Electron microscopy was thus able to differentiate the damage caused by the 
presence of toxic gliadin peptides in the culture medium (Townley et al., 1973). 
c. Using the tanned red blood cell technique, it was shown that antibodies against the 
fractions from ion exchange of the gliadin digest were highest against Fraction 9, 
suggesting that in patients with active CD, undigested peptides from Fraction 9 had 
mounted a significant immune response, compared with other fractions, which had 
presumably been better digested (Cornell,1974). 
d. The xylose tolerance test showed that in children with CD in remission, some damage 
to the small intestine was indicated by reductions in levels of xylose excretion in their 
urine after ingestion of Fraction 9. No significant changes in urinary xylose were seen 
with the other fractions when combined (Cornell & Townley, 1973). 
e. Fraction 9 displayed high activity in a fetal chick assay and was shown to contain two 
active peptides, one corresponding to residues 5-20 and the other to residues 75-86 of A-
gliadin (Cornell et al., 1992). When these peptides were subjected to specific deletions of 
amino acids it was found that the most active peptide was the nonapeptide 11-19 while 
the  dodecapeptide 75-86 was seen to be close to the maximum activity in this group of  
peptides (Cornell & Mothes,1993,1995). 
f. Coeliac mucosal digestion of each of these peptides showed that undigested residues of 
octapeptides were obtained in greater amounts than those obtained from digestion with 
mucosa from normal individuals (Cornell & Rivett, 1995; Cornell, 1998).  
g. Importantly, these undigested octapeptides were found to contain sequences of amino 
acids found by ourselves and others to be associated with toxicity (De Ritis et al.1988; 
McLachlan et al., 2002).  
The connection between the most active fraction and undigested peptide residues being 
found in the same fraction indicates that the reason for this toxicity is due to insufficient 
activity of an enzyme in patients with CD. This proposal was first put forward by Frazer et 
al. (1959) on the basis that patients on a gluten-free diet relapsed after being fed a peptic-
tryptic digest of gluten, but this did not happen when the gluten digest was subjected to 
further digestion with a hog intestinal extract. 
It must be said that apart from our work and that of our collaborators, little else has been 
contributed to support an enzyme deficiency in CD. Perhaps some commonality is seen in 
the work on a 33-mer peptide of α-2gliadin, which was observed to be difficult to digest 
(Shan et al., 2002).These undigested peptides have significant immunogenicity which are 
thought to be responsible for toxicity, but so far, no toxicity data have been presented. 
Current work in this area is directed towards an understanding of the type of enzyme which 
appears to be missing or defective in CD. One way of gaining this information is by 
examining the structures of peptides which remain after coeliac mucosal digestion. The 
other way is to examine the types of peptides that are the most effective for digesting the 
gliadin down to small fragments which are no longer toxic in the assay employed. These 
approaches will be discussed in Sections 5 and 6 of the chapter. 
4. A unified theory of CD 
Quite often, CD is referred to an autoimmune disease, meaning that the body, by mistake, 
produces antibodies that damage its own tissues (Maki, 1996). Although antibodies are 
produced in patients with CD to tissue transglutaminase (tTG), which potentiates the action 
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of dietary gluten, the source of the problem is a group of proteins which are foreign to the 
body and if these are not broken down to amino acids and small peptides, an 
immunological response will be mounted and tissue will be damaged. If the proteins are 
broken down to amino acids and small peptides, the tissue will remain in a normal and 
healthy state (Cornell & Stelmasiak, 2007). 
These harmful proteins are present in wheat, barley and rye and to a much smaller extent in 
oats. The wheat gluten contains two major groups of proteins, referred to as glutenins and 
gliadins. The latter group contains proteins of lower molecular weight (≈ 30,000 Daltons) 
and are regarded as being the more harmful to those with CD. Most work has been done on 
these gliadins, not only because of their higher toxicity, but also because they are simple 
chain proteins and can be readily extracted from gluten or flour by 70% v/v ethanol 
(Mothes et al., 1999). They are referred to as prolamins. Prolamins from rye are called 
secalins, those from barley as hordeins and those from oats as avenins. 
Some humans are born with a genetic predisposition to CD which may become obvious 
after exposure to dietary gluten, as when an infant is introduced to solid foods. The HLA 
typing with the genes referred to as DQ2 and DQ8 and genetic testing is useful for 
excluding a diagnosis of CD. However, only about 3% of people with either or both these 
genes will develop CD. The prevalence of HLA-DQ2 alone is about 25% in the North 
European population yet only about 1% has CD, suggesting that additional genes are 
involved in CD (Kagnoff, 2007). Mäki and Collin (1997) reported that more specific factors, 
probably non-HLA genes are involved. Both genetic and environmental factors appear to 
play a role in development of CD. 
The older theory of an enzyme deficiency in CD must be given serious consideration 
because it is hard to imagine what type of substance in a hog intestine extract, other than an 
enzyme, can result in detoxification of a gluten digest. (Frazer et al., 1959). Moreover, the 
work summarised in Section 3 by the writers carries some weight insofar as certain toxic 
peptides in A-gliadin seem not to be completely digested by mucosa from children with CD 
in remission. Strengthening this even more is the finding of motifs of amino acids from two 
peptides which appear in the residues from mucosal digestion of children with CD in 
remission that we and others have shown to be associated with the toxicity of gliadin  
The concept of an enzyme deficiency is more plausible than the proposal that proline-rich 
epitopes are exceptionally resistant to enzymatic processing (Hausch et al., 2002). ‘In vitro’ 
mucosal digestion with small intestinal homogenates from normal individuals show 
consistently lower amounts of peptide residues from toxic peptides compared to residues 
from coeliac mucosal digestion. However if the amounts of peptides used are excessive, 
compared with mucosal dry matter, one would expect more residual peptides from the 
normals. For those interested in the historical overview of the assays and toxicity studies, 
the reader is referred to an older review (Cornell, 1996). 
Coupled with an enzyme deficiency is the need to recognise the plethora of immunological 
reactions that appear to be responsible for the pathology of CD. We fully affirm the 
importance of immunological reactions in the pathogenesis of CD as proposed by Falchuk 
and Strober (1974). However, Biagi et al. (1999) dispute that the pathology is the result of 
abnormal presentation of gliadin. We contend that these pathogenetic mechanisms are the 
result of partially digested gliadin (or other toxic cereal peptides) that accumulate in the 
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small intestine as the result of an enzyme deficiency. The immune response might be 
magnified by prior cytotoxic action. Experiments with two types of toxic peptides we have 
described tend to verify this view.  
 Several hypotheses have been proposed to account for the susceptibility of certain 
individuals to CD. Two major hypotheses have been referred to as the Enzymopathic 
(enzyme deficiency) Hypothesis (Frazer et al., 1959) and the Immunological Hypothesis 
(Falchuk & Strober, 1974). A third hypothesis is based on a defect in the permeability of the 
intestinal mucosa (Bjarnason & Peters, 1983). 
The evidence for damage to tissue as a result of immunological mechanisms is 
overwhelming but the argument that it represents an aberrant reaction because of abnormal 
presentation of gliadin is less convincing (Biagi et al., 1999). The modern view is that HLA 
class II molecules in antigen-presenting cells expose processed peptides to 
immunocompetent T-cells thereby triggering pathogenesis (Sollid, 2002).T-lymphocytes 
respond by releasing cytokines which cause inflammation and damage of enterocytes and 
other cells in the small intestine. 
Vader et al (2002) studied gluten specific T-cell responses in HLA-DQ2 positive adult 
patients with CD and showed that they were directed at multiple peptides derived from 
gliadin and glutenin. There is a broad spectrum of sensitivity to gluten in patients with CD 
and this can be explained partly by multiple levels of immune regulation (Schuppan & 
Hahn, 2002) and partly by enzymatic processes governing the extent of digestion of gliadin 
peptides (Cornell & Rolles, 1978). 
Regarding the hypothesis of permeability defect in the intestine mucosa (“Leaky Gut” 
syndrome), the general argument is that there is increased permeability of the epithelium. 
One group claims that this is caused by a myosin variant and leads to increased antigen 
presentation(Monsuur et al.,2005) whilst another group claims that sustained release of 
zonulin occurs, concomitant with an increase in permeability (Drago et al.2006). The zonulin 
release was less in normals, suggesting better digestion of gliadin occurred. 
The writers have proposed a “Unified Hypothesis of CD” (Cornell & Stelmasiak, 2007) to 
account for the specific causative effects of gluten, which cannot be explained simply by 
saying that gliadin peptides are difficult to digest. Certainly, there has been some evidence 
to suggest that individuals other than those with CD have problems caused by gluten-
containing food (Jones et al., 1982). The fact of the matter is that the majority of people do 
not encounter this problem, except for some first degree relatives, who have been shown to 
have partial deficiency in regard to their ability to digest gluten completely (Cornell & 
Rolles, 1978). The etiology of CD has many similarities to that of dermatitis herpetiformis, 
except that the manifestation of this condition is the formation of a rash and itchiness (Fry, 
1992). Both are quite different in etiology to wheat allergy. 
It raises the important point that some gliadin peptides may not inflict damage to cells until 
they are modified in some way. Mölberg et al. (1998) have shown that tissue 
transglutaminase appears to modulate the reactivity of gliadin-specific T-cells. This effect is 
mediated by a specific deamidation of gliadin peptides which binds them strongly to DQ2 
molecules and allows recognition by certain T-cells. It is an important example of enzymatic 
modification of antigens that results in activation of pathological processes. 
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Returning to the basic etiology of CD, the writers maintain that there are multiple peptides 
in a peptic-tryptic-pancreatinic digest of gliadin that require a specific enzyme for complete 
digestion to harmless peptides. This enzyme is deficient or defective in individuals with CD. 
The enzyme attacks peptides that contain certain sequences of amino acids that are present 
in the three coeliac-toxic cereals, wheat, rye and barley. Without this enzyme patients with 
CD are unable to digest the gliadin peptides and damage to the small intestine mucosa 
ensues (Cornell & Stelmasiak, 2007).  
Two different types of active peptides have been discerned and the use of synthetic peptides 
of A-gliadin have made it possible to say that a group of serine-containing peptides such as 
11-19 of A-gliadin have displayed potent cytotoxicity, while those such as tyrosine-
containing peptide 75-86, have potent immunogenicity (Cornell&Wills-Johnson,2001).It is 
because of the fact that both these peptides are not digested by coeliac mucosa down to 
small harmless peptides, but instead resist digestion past the octapeptide stage, that we 
invoke the concept of damage both by cytotoxic and immunologic mechanisms (Cornell & 
Stelmasiak,2007). The latter are suggested from their ability to produce interferon-γ from red 
blood cells from patients with CD (Cornell et al.,1994)  This is not so for the serine-
containing group of toxic peptides. Hence the writers have proposed a hypothesis which 
combines the two main theories, henceforth referred to as the Unified Hypothesis (Cornell & 
Stelmasiak, 2007). The etiology and pathogenesis of CD are closely linked in complex events 
and this term seems to be a satisfactory way of explaining all of those events according to 
present day knowledge. 
Other workers have pointed out the difficulty of digesting certain proline-rich peptides 
which can involve immunological reactions leading to intestinal damage. Hausch et al. 
(2002) comment on immunodominant epitopes that are considered difficult to digest 
because of the low activity of enzymes capable of N-terminal and C-terminal attack on 
proline residues (DPPIV and pancreatic endoproteases respectively). These epitopes are 
probably more important from the point of view of their particular key amino acid 
sequences, particularly ones that contain tyrosine, rather than their high proline content. The 
bioactivity of wheat and problems with the digestion of some of its components in CD have 
been pointed out (Cornell & Hoveling, 1998). The 33-mer peptide of α-2 gliadin (Shan et al., 
2002) is also difficult to digest and again, the repeating sequences containing proline, 
tyrosine and glutamine are probably of importance to its immunogenicity. From a clinical 
point of view, they also provide the rationale for the application of enzyme therapy. Sollid 
offers an explanation that proline has a dominant role in the specificity of tissue 
transglutaminase and could facilitate binding to the above 33-mer fragment (Sollid, 2002). 
5. The basis of enzyme therapy 
The elucidation of structures in gliadin that are resistant to digestion by remission coeliac 
mucosa has provided a promising basis for treatment, providing the amount of gluten 
ingested is not excessive. The way in which this could be evaluated was offered by the use 
of the rat liver lysosome assay, based on the principle that the lysosomes are disrupted by 
toxic gliadin peptides. If the gliadin is detoxified by an enzyme capable of digesting the 
peptides responsible for damage to the lysosomes, that enzyme could form the basis of 
suitable therapy for patients with CD. 
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It was kept in mind that, to be effective therapy, the product would have to be able to 
counteract 50mg of gluten/day (Catassi et al.2007). Hence there would be no way of 
achieving high degrees of protection unless the patients remained on a nominal gluten-free 
diet in order to achieve a degree of protection and used enzyme therapy as an adjunct 
treatment, i.e., as a safeguard. 
Another use of the rat-liver lysosome assay, which throws direct light on the enzyme 
deficiency in CD, is the way it was used to show that there was residual activity in Fraction 
9 after incubation of small intestinal mucosa from children with CD in remission. In five 
experiments, the mean reduction in absorbance was 45% for coeliac mucosa and 23% for 
normal mucosa. Controls without Fraction 9 registered 18%, close to the normal mucosa. 
Thus, there appears to be incomplete digestion of Fraction 9 in those with CD compared 
with normals (p<0.001) (Cornell & Townley, 1973b). 
This conclusion had also been indicated by toxicity studies with fetal rat mucosa (Cornell et 
al., 1988) and gave confidence in the use of lysosomes as a screening test. Similarly, good 
correlations between the lysosome screening test and results of fetal chick assay were 
obtained (Cornell & Mothes, 1995).As an animal model for studies of CD small intestinal 
tissue from fetal animals has been very useful, presumably because these animals do not 
have fully developed protective enzyme systems. This, of course, is completely in agreement 
with the idea of defective digestion being a key component of tissue damage by gliadin 
peptides. 
The authors embarked on a program to study adult animal intestine with a view to 
determining if complete digestion of toxic gliadin peptides could be achieved and thereby 
used as a means of providing the missing or defective enzymes in patients with CD. In 
these studies of animal intestinal mucosa, the authors showed that no significant toxic 
peptide residues remained after digestion of the gliadin digest with the normal human, 
pig, cow and sheep intestinal mucosa, whereas toxic residues were obtained after 
incubation with remission coeliac mucosa. Highest degrees of protection (85-90%) against 
gliadin were offered in the lysosomal assay by the pig and cow extracts, followed by 
human and sheep (70-76%). By contrast, remission coeliac mucosa offered only 15% 
protection, not very different from the controls without mucosa (Cornell & Stelmasiak, 
2004). 
These results led to our first experiments with animal mucosa in which we decided to 
investigate the use of pig mucosal extracts for enzyme therapy in CD. It was of great 
importance to note that digestion by the intestinal mucosa of these animals was comparable 
to that by normal human mucosa and far more complete than that seen in patients with CD 
in remission. These animals have been ingesting various forms of gluten for millions of 
years longer than have humans and have evolved efficient digestive systems. Some humans 
are well behind in this aspect and conjecture on this matter is strengthened by a further 
group of individuals who have varying degrees of gluten intolerance (Van Heel & West, 
2006). 
Pig intestinal mucosa was chosen for a series of investigations designed to show that the 
active principle in this mucosa was an enzyme. It was therefore necessary to begin with 
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large quantities of pig mucosa and refine it to the extent of producing enough active enzyme 
to be characterized and possibly identified. 
The evaluation of products from all stages of the purification were monitored by the rat liver 
lysosome assay (refer Section 2) using a 2 hour at 37°C period of incubation of the fraction of 
pig mucosa with the gliadin digest before testing residual toxicity against the lysosomes. 
When the enzyme was effective, the residual toxicity was low; hence high values of  
protection (P) were obtained. 
The first stage of refinement involved the use of an ion-exchange resin. Ion exchange resins 
were considered favourably because their bead form allows high flow rates and they can be 
readily regenerated using sodium hydroxide. Pilot scale experiments using filtered extract 
from 4kg pig intestinal mucosa yielded a product enriched in gliadin detoxifying enzymes 
from the use of the weakly basic Amberlite anion exchange resin, IRA95. 
The active principle in the pig intestinal mucosa was found to be bound by the ion-exchange 
column at pH 7.5 and could be eluted by phosphate buffer of pH 5.0 containing 0.3mol/L 
sodium chloride. The eluate was desalted by membrane filtration and freeze dried. A 
refined enzyme extract was obtained as a fawn-coloured powder in yields of 3-4% on freeze-
dried mucosa extract. 
Further fractionation using laboratory-sized columns of the weakly acidic (carboxymethyl) 
ion exchanger CM Sephadex C50, were used to prepare more enriched fractions. In this case, 
the most enriched fraction was obtained by raising the pH of the phosphate eluting buffer 
(0.05 mol/L) and applying a linear salt (sodium chloride) gradient to 0.3 mol/L. The most 
active fraction (Fraction 4) eluted at pH 6.2 and 0.20 mol/L sodium chloride. 
The specific activity of each of the most active fractions was calculated from the results of 
the rat liver lysosome assay. Results of these evaluations are shown in Table 1. Note that 
specific activity is calculated from protection (%) offered per mg sample. 
 
Sample Specific Activity (P/mg) 
Crude enzyme extract 12 
Fraction from Amberlite IRA 95 17 
Fraction 4 from CM Sephadex C-50 34 
Table 1. Specific activity of pig extract and crude fractions thereof 
Other enzyme levels determined on Fraction 4 were protease levels by the benzoylarginine 
ethyl ester (BAEE) method, which is a good measure of total protease levels (Arnon,1970)  
Refer Table 2. 
PEP levels in Fraction 4 were carried out using Z-gly-pro-p-nitroanilide ( Kocna et al., 1980). 
Crude pig extract showed levels of 6.4 × 10-4 U/mg and this was increased to 2.1 × 10-3 
U/mg after ion exchange on Amberlite IRA 96. Pure PEP (Seikagu, Japan) has a specific 
activity of 20 U/mg so the above levels showed that PEP was not an important contributor 
to activity, as measured by the lysosome assay. 
An important finding was that prolidase activity, measured by the ability of the enzymes 
present to hydrolyse Ac-Pro-Gly was 0.025 U/mg in the crude extract while Fraction 4 was 
0.06 U/mg (Cornell et al., 2010). 
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Neither the crude extract nor the material absorbed on IRA 95 contained any significant 
amounts of enzyme activity measured according to the BAPNA (benzoylarginine p-
nitroanilide assay) (Gravett et al., 1991). This assay was used extensively in studies of 












1 17.7 unabsorbed 45 0.10 4.3 × 10-4 
2 5.2 change of pH 51 0.45 5.6 × 10-5 




90 0.10 5.8 × 10-5 




18 0.78 1.8 × 10-5 
Starting 
Extract 
- - 68 0.36 6.4 × 10-4 
*4mg fraction/assay tube 
Table 2. The results of activity and enzyme assays on fractions obtained by chromatography 
of the refined pig intestinal extract on CM Sephadex C-50 Column (3.2 × 20 cm). 
Fraction 4 was digested with trypsin and submitted for mass spectrometric fragmentation 
analysis but the only known protein found was pig albumin which has a molecular weight 
of 68KDa, similar to that of the active enzyme produced during processing, even though 
temperatures were held at 5°C. Without processing, the active enzyme in fresh pig extract is 
in the range of 120-170kDa obtained using Sephacryl S300, but Fraction 4 appears to have a 
very broad peak of activity between 50 and 80 kDa, which explains the contamination with 
pig albumin. No matches were obtained between the analysed sequences of the enzyme and 
the library of known pig enzymes. Specific activities of the higher (80 kDa) and lower (50 
kDa) fractions on Sephacryl S-300 were 90 and 36 respectively, higher than the result (17) for 
the starting material.  
Fraction 4 was further purified using size exclusion HPLC on Bio Sep SEC-S2000 in 0.05 
mol/L phosphate buffer, pH 6.8. The column allowed applications of up to 3mg of sample. 
Highest activity was obtained in fractions that corresponded to molecular weight in the 
range 60-100 kDa. By absorbance at 214mm, 6 peaks were obtained, with the highest 
lysosomal activity in the range corresponding to peaks 2 and 3. Some autolysis of the 
enzymes may have occurred during processing. These results are in agreement with the size 
exclusion experiments using Sephacryl S-300 (refer Table 2). 
Estimates of specific activity on the fractions of highest lysosomal activity are in the range 
180-220. This has allowed partial sequencing of active enzymes but the samples were not 
pure enough to show significant homology between the active enzyme and known enzymes 
present in the pig. 
Fractionation of pig small intestine extract has been useful for characterising the active 
enzyme, according to monitoring with the rat liver lysosome assay. Among these can be 
listed: 
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a. Optimal pH of 8.4 
b. Strongly inhibited by phenylmethyl sulfonyl fluoride (PMSF) 
c. Unstable to heating at 85°C 
d. Unstable to acid (pH 2) 
e. Molecular weight may be greater than 100 kDa before autolysis 
The identity of the enzyme in pig is likely to be similar to that of the missing enzyme in 
humans. It seems to fit the general description of a prolidase and appears to attack coeliac-
active peptides on the N-terminal side of proline residues and is a necessity for digesting 
key motifs associated with toxicity that contain proline. Hence the enzyme is likely to be an 
imino-oligopeptidase, a proline specific enzyme not implicated in detoxification of gliadin 
up to this time. 
In conclusion, an enzyme capable of detoxifying gliadin was found in pig intestinal mucosa 
and appears to be a prolidase. It can be partially separated from prolyl endopeptidase (PEP) 
which has less activity than the prolidase in the rat liver lysosome assay, considered to be 
relevant to measurement of protection against gliadin toxicity. 
Enrichment of the prolidase can be achieved by elution of higher salt concentration in 
phosphate buffers on weakly acidic cation exchanges or by reason of its higher molecular 
weight. The prolidase has a higher pH optimum (8.4) compared with PEP (7.5). 
Because of the ability of the prolidase to attack the N-terminal side of proline residues, it is 
ideal for disrupting toxic residues common to wheat, rye and barley such as QQQP, QQPYP 
and PQQPY. By this means, toxicity of peptides derived from these three cereals is able to be 
curtailed and small amounts of the cereals will be able to be tolerated. PEP attacks these 
sequences on the C-terminal side of proline residues, which may not be as effective in 
reducing toxicity. Even with sequences such as 11-19 of A-gliadin (QNPSQQQPP), that 
appear to be only present in wheat, it was observed(Cornell&Rivett,1995) that the N-P bond 
remained intact, which would not be the case after attack by a prolidase. 
6. Strategies for treatment of CD 
Since the publication of the first clinical trial of enzyme therapy, other groups have also 
contributed to knowledge in this area. Shan et al. (2002) have shown that a 33-mer T-cell 
stimulatory peptide, which appears to cause difficulties in digestion by normal digestive 
enzymes, can be degraded by prolyl oligopeptidase from Flavobacterium meningosepticum. 
Others have shown that this enzyme has only limited efficiency in the detoxification of 
gliadin peptides in CD (Matysiak-Budnik et al., 2005). Furthermore this enzyme is not 
deficient in remission coeliac mucosa, as one would expect if it were a key factor (Donlon & 
Stevens, 2004). 
Other types of enzymes which have been investigated for use in enzyme therapy are those 
from Aspergillus niger. Stepniak et al. (2006) have identified a prolyl endopeptidase (AN-
PEP) from A.niger which was able to degrade T-cell stimulatory peptides in vitro under 
conditions like those in the gastrointestinal tract. Its action was considerably faster than the 
prolyl endopeptidase from Flavobacterium meningosepticum. 
Enzyme therapy is based on the premise that the digestive deficiency in CD can be corrected 
by the oral administration of special enzymes formulated in enterically coated tablets so that 
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the contents can be protected from the action of the gastric juices, allowing the required 
enzymes to pass through to the small intestine where they can complete the digestion of 
gluten peptides down to harmless small peptides and amino acids. It may not be necessary 
in some cases to enterically coat the tablet, as some enzymes such as the one from A.niger is 
stable at pH 2 and is completely resistant to digestion with pepsin. However, its pH 
optimum is 4-5, which is well below that of the contents of the small intestine. 
A totally different approach has been taken by Anderson et al. (2000). Since their discovery 
of a transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope, these 
workers have pioneered the way for antigen-specific immunotherapy in CD. Using fresh 
peripheral blood lymphocytes from subjects undergoing challenge from gluten, interferon-γ 
release was elicited by a 17-amino acid peptide corresponding to residues 57-73 of A-
gliadin. This peptide has the structure QLQPFPQPELPYPQPQS, with E at residue 65, being 
the result of deamidation of the corresponding glutamine residue. 
It is interesting to note that tyrosine is present in this peptide as part of the PYPQ motif that 
could be important in relation to difficulty of proteolytic digestion. However, it will be 
important to consider sequences in the other coeliac-toxic cereals rye and barley, which 
feature PQQPY as being common in all three cereals implicated in CD (McLachlan et al., 
2002). 
If a suitable vaccine is able to be made, some liberties with respect to ingestion of gluten are 
expected to be allowed. However, the use of a safeguard based on enzyme therapy will 
probably still be necessary as the enzyme recommended is able to detoxify peptides that 
produce an immune response and also those that have cytotoxic action(Cornell et al.,2010) . 
Plant enzymes were considered a better option than animal enzymes, despite the fact that 
the enzyme most likely to be missing or defective in CD is bound to be closely related to one 
from a higher animal. The reason for not continuing with our plans to market an animal-
based product were due to the prevalence of animal diseases, such as bovine spongiform 
encephelopathy (BSE or “mad cow disease”) and porcine adenoviruses. In addition, 
religious restraints put on products from these two animals in particular would be a barrier 
to their marketing. Other people may have dietary concerns. It was therefore decided to 
look at plant sources and among these were papaya latex, bromelain, chymotrypsin, fungal 
proteases and Aspergillus oryzae. These materials were compared against pure papain and 
prolyl endopeptidase. 
It was found that papaya latex concentrate with a protection (P%) of 93 was far the most 
active preparation. Crystalline papain, the major papaya enzyme, gave a P value of only 7. 
Prolyl endopeptidase (P=35) gave results comparable to highly purified prolyl 
endopeptidase from Chryseobacterium meningosepticum, but in terms of specific activity, it 
was much lower than pure caricain, which gave a result of 9,412 (see later in this section). 
The evaluation of these sources of enzymes for purpose of making an enzyme supplement 
to digest gliadin efficiently, was carried out using the rat liver lysosome assay (refer Section 
2). Up until this stage, the assay was used for evaluation of the toxicity of gliadin peptides 
and for testing the residual toxicity (activity) after small intestinal mucosal digestion. By 
incubating the toxic gliadin digest with a sample of each enzyme, a comparison of the 
effectiveness of these enzymes could be made. A two hour period of incubation of the 
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enzyme with the gliadin digest at 37°C was given before testing the residual activity of the 
gliadin against the lysosomes. Calculations of specific activity were also able to be made by 
dividing the protection (P %) by the mass of enzyme-containing product. 
The enzyme caricain (papaya protease omega) is a cysteine protease (Dubey et al., 2007) 
found in the latex of Carica papaya. Caricain is one of the several proteases present which 
degrade proteins. They are endopeptidases of broad and narrow specificity, with the major 
ones being papain, chymopapain, glycyl endopeptidase and caricain. They are synthesised 
by the plant as inactive forms (zymogens) that are converted into the active forms within a 
short time after the latex is removed from the plant (Azarkan et al., 2003). 
The optimum pH of caricain is 6.8 and its isoelectric point is 10.5. As expected, it is eluted 
from cation exchangers such as SM Sephadex only at high concentrations (>0.7 mol/L) of 
sodium chloride. It is classified internationally as E.C.3.4.22.30 and its function is that of an 
endopeptidase. The structure consists of a proenzyme of 106 amino acids and an active 
enzyme of 242 amino acids (Groves et al., 1996). Recent experiments with purified carciain 
indicated that the reaction which controls detoxification of a wheat gliadin digest at pH 7.5 
and 37°C is a 1st Order reaction with rate constant 1.7 × 10-4 sec-1 (Cornell & Stelmasiak, 
2011). The enzyme was able to offer about 80% protection to rat liver lysosomes when used 
at a concentration of 1.7% on substrate after 2 hours incubation at 37°C, representing a 
specific activity of 9,412. These experiments were valuable in demonstrating that caricain is 
a very effective enzyme in detoxifying gliadin and promises to be a prime starting point for 
enzyme therapy. Papaya enzymes are deemed to be extremely safe (Australian Government 
Report, 2008) if extracted from the fruit of Carica papaya. 
A further development in the use of papaya was the concept of synergism between two 
active enzymes. This was evident with combinations of the pig intestinal extract and the 
papaya latex. Table 3 shows that this combination showed a significant improvement over 
what would be expected from the mean protection (P %) of two separate batches of pig 
intestinal extract and papaya latex. The experiment was repeated with bromelain but, in this 
case, there was nothing to be gained in protection although the combination gave higher 
protection than expected from the mean. There has been a report of combination enzyme 
therapy using prolylendopeptidase and an enzyme from germinating barley(Siegel et 
al.,2006)  and this is worthy of further study with plant enzymes. 
 
Enzyme 1 P (%) Enzyme 2 P (%) Combination P(%) 
Pig intestinal extract 61 Papaya latex 71 92 
Pig intestinal extract 48 Papaya latex 54 68 
Bromelain 21 Papaya latex 62 61 
Note: Each enzyme evaluated at 6mg/mL in mixture of two and also at 12mg/mL separately. Results 
are the means of two determinations. 
Table 3. Results of some combinations of crude enzymes to test for synergistic activity. The 
protection index (P%) from the rat liver lysosome assay was used as the indicator. 
7. Preliminary clinical studies 
Clinical studies to confirm the value of enzyme therapy were of prime importance as only in 
vitro testing had been carried out up to the stage of using animal intestinal extracts. All the 
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in vitro experiments had indicated that pig intestinal extracts completed the digestion of a 
toxic gliadin digest. The first trial was conducted to verify that these extracts could complete 
digestion in vitro. A large scale batch of pig intestinal extract was prepared for a clinical trial 
at The Royal Melbourne Hospital. This trial was carried out to test the efficacy of such an 
extract in countering the effects of a mild gluten challenge in patients with CD. Participants 
were 21 biopsy-proven adults with CD who were on a gluten-free diet. The design of the 
trial was of double-blind crossover type using the extract in enterically coated capsules and 
a placebo in the same type of capsules. Six patients were also biopsied and histological 
changes compared for treatment and placebo (Cornell et al., 2005). 
In those patients who developed symptoms (8 of the 21) these symptoms were ameliorated 
with the enzyme (p<0.02), suggesting that the therapy was beneficial. Further evidence was 
provided by the histological studies which showed that 5 of the 6 patients chosen at random 
showed small bowel abnormalities at the start of the trial, but that further damage as a result 
of the gluten challenge was reduced in 3 of these patients. Antibodies to tTG and gliadin 
(Dahele et al., 2001) were roughly correlated with severity of histological damage at the start 
of the trial but no significant reduction in titres was obtained during the course of the trial. 
This clinical trial was successful in demonstrating that the enzyme deficiency in coeliac 
disease could be partly corrected by the use of enzymes in a tablet administered orally at the 
start of a meal. As the tablets were enterically coated, it allowed the enzyme to pass through 
the stomach unaffected by the hydrochloric acid and pepsin present and to pass into the 
small intestine where it rapidly disintegates to release the enzymes for complete digestion of 
any small amount of gluten that may be ingested. In this way it acts as a safeguard and 
allows more latitude in selection of food. It will thus take the worry out of eating at 
restaurants, homes of friends and other places where there is a question about the gluten 
content of the food. It could represent the most important breakthrough in patient 
management since the introduction of the gluten-free diet over 50 years ago. 
A further clinical trial is being conducted to evaluate histological changes in the small 
intestine of coeliac patients brought about by enzyme therapy using plant enzymes. The aim 
of this trial is to determine whether the active enzyme in papaya is able to repair damage 
small intestinal mucosa caused by small amounts of gluten in the diet. It will involve 20 
biopsy-proven participants with CD who have been on a gluten-free diet for at least 12 
months. Participants will undergo biopsy at the beginning and end of the test period (3 
months) while taking either enterically coated tablets of a papaya oleo-resin extract or a 
placebo. Thus it is a double-blind design but without crossover and has a longer treatment 
period than the first trial, but without defined gluten challenge. As for the first trial, blood 
tTG levels are being monitored; participants with higher than normal levels have been 
favoured for this trial. Changes in small bowel histology during the course of treatment are 
the major indicators of whether the enzyme is effective, with confirmation from the 
examination of changes in the participants on placebo. 
A combination of a gluten-free diet and enzyme therapy should ensure that traces of gluten 
in the diet are eliminated, thus providing a sound basis for maintaining the small intestine 
in sound condition. Otherwise, traces of gluten can bring about alterations in architecture of 
the small intestine, particularly in the region of the duodenum, and this is seen in a 
significant number of patients on a normal gluten-free diet without the benefit of enzyme 
therapy. In the light of experience, the use of such an enzyme safeguard is justified because 
 
Celiac Disease – From Pathophysiology to Advanced Therapies 
 
156 
it is well known that contamination alone makes the gluten content of coeliac diets doubtful. 
Added to that are the problems of inadequate labelling and the lack of knowledge of the 
disease by some food suppliers. 
We are confident that enzyme supplementation will detoxify gluten in not only wheat, but 
also in rye, barley and oats. It will be a safer alternative than drugs and will be ready long 
before any other techniques can be implemented such as changing gluten into a non-toxic 
form or commercial production of a safe vaccine against gluten. We are convinced that our 
work with enzyme supplements is critical for the better management of coeliac disease and 
will reduce the incidence of ongoing intestinal dysfunction. 
All of our work on digestion of gliadin is in complete agreement with the experiments of 
earlier workers, who found that the combined amino acids, present as building blocks in 
gluten, are not injurious to patients with gluten-sensitive enteropathy. It is extremely 
important to note that virtual complete digestion of gluten guarantees that there will be no 
adverse reaction to that mixture of amino acids and small peptides, in contrast to the disease 
state, where incompletely digested larger peptides are capable of causing damage by 
various mechanisms. The use of enzyme therapy is a significant step towards ensuring that 
these incompletely digested gluten peptides are at an absolute minimum concentration in 
the small bowel. 
We are aware of other approaches to the problem of gluten ingestion but in the case of long-
term solutions, there is still the likelihood of enzyme therapy being required as it targets all 
the toxic peptides, not just the immunoactive ones. Enzyme therapy will still be needed as a 
safeguard. 
Early diagnosis of CD and enzyme therapy will safeguard against damage and 
consequences of long-term ingestion of gluten (osteoporosis, malabsorption of vital 
nutrients and lymphomas) and should reduce concerns about children and adults being 
uncertain of the gluten content of food, particularly that prepared outside the home. 
Enzyme therapy provides a form of natural product therapy based on sound scientific 
principles for treatment of a number of conditions relating to gluten intolerance. It has 
further advantages of easy administration and its low cost could compensate for the extra 
costs of gluten-free foods, particularly if greater emphasis was placed on fruit, vegetables, 
meat and fish rather than gluten-free cakes and pastry. Gluten-free bread, cereals and pasta 
will need to be the main special foods purchased. 
Enzyme therapy is now becoming well documented, although there is still a degree of 
scepticism, brought about by a strong leaning to the “immunological” theory of coeliac 
disease, rather than the older “enzyme deficiency” theory. Market trials are showing the 
value of a tablet containing the active enzyme, in that symptoms are markedly reduced. A 
significant percentage of coeliacs on a gluten-free diet are still experiencing symptoms of a 
mild to moderate nature and are thus risking further damage to their small intestine. Others 
with relatively few symptoms are certain to have some abnormalities in that region of the 
gut. 
At present, we are considering commercialization of tablets manufactured to contain 300mg 
of crude papaya enzyme (15mg pure caricain) one of which is able to detoxify about 1.5g 
gluten, about 5 dry cracker biscuits, or one third of a slice of bread. 
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8. Applications of enzyme therapy 
Enzymes are such versatile materials that their application to therapy should be 
widespread. Before enzyme therapy was considered for CD, enzymes were on the market 
for pancreatic insufficiency. Lipases, amylases and proteases are commonly present, in 
capsule or tablet form, that are useful for individuals with this condition. Pepsin, bromelain 
and papain are often used in conjunction with such enzymes to provide products that are 
useful as digestive supplements. For lactose deficiency, tablets containing the enzyme (β-D-
galactosidase) can be used or drops that can be added to milk or infant formulae. Apart 
from the present application of enzyme therapy to CD, there are other conditions where 
gluten is considered to be harmful and where a gluten-free diet is recommended. One such 
condition is dermatitis herpetiformis, in which the small intestine often shows only patchy 
damage, but the disease manifests itself as an itchy rash (Fry, 1992). A gluten-free diet is 
essential in order to prevent the troublesome rash but also to guard against damage to the 
small intestine. So far, we have been only able to test enzyme therapy with caricain in one 
individual and the results are promising insofar as the effects of a wheat-based cereal and 
bread were almost eliminated by the use of one tablet at the beginning of each breakfast 
meal. A small controlled clinical trial is now being planned. 
Gluten may be a dietary factor in certain neurological disorders, e.g. schizophrenia. Dr 
Curtis Dohan was a pioneer of work on the harmful effects of gluten in schizophrenia. One 
study involved 110 patients, half of whom were on a diet free from cereal grains and milk. 
Those on the special diet showed improvement in their condition and were discharged 
almost twice as quickly (Dohan&Grasberger, 1973).A subsequent trial showed that 
schizophrenics maintained on a cereal grain-free and milk-free diet regressed during a 
period of a “blind” gluten challenge (Singh&Kay, 1976) .The cause of these ill-effects appear 
to center around gluten peptides that act as opioids. (Fukudome & Yoshikawa, 1992). 
As schizophrenia is a very serious neurological illness, the use of enzyme therapy in 
conjunction with a gluten-free diet could be a useful form of patient management. If enzyme 
therapy and a gluten-free diet were used in conjunction with the medication it could turn 
out that the amounts of neuroleptic drugs used at present could be reduced, which would 
almost certainly mean less serious side effects. 
Autism is another neurological condition which is often accompanied by gastrointestinal 
symptoms. Since the first report from Asperger (1961), who noted that many children with 
CD showed psychiatric conditions, there has been a strong focus on autism and its 
associated difficulties in intellectual and social development of the young. Because gluten 
contains many opioid sequences, these have again been thought to be a direct cause. In this 
condition and others with a neurological basis a gluten-free diet is helpful suggesting a role 
for enzyme supplementation. 
Irritable bowel syndrome (Biesiekierski et al., 2011) is a condition in which abdominal pain, 
flatulence and bloating are commonly observed. It is commonly believed that wheat and/or 
gluten is responsible for many individuals with this condition and this has been largely 
responsible for the proliferation of many gluten-free foods. Better public education on CD 
has perhaps given the lead in this direction. However, those suffering from irritable bowel 
syndrome appear to outnumber those with CD. 
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Further work in this area will be undertaken to determine if enzyme therapy will be helpful. 
It may be successful in some individuals and not in others as there appear to be a number of 
dietary triggers in irritable bowel syndrome (Shepherd et al., 2008). Ulcerative colitis and 
Crohn’s disease are examples of conditions where a gluten-free diet has been of some help, 
suggesting that enzyme therapy could be a useful adjunct treatment. 
Another application of enzyme therapy could be in management of patients with silent CD. 
This condition is where the individual has villous atrophy yet displays no symptoms. 
Examples were provided by Matysiak-Budnik et al (2007) who studied individuals 
diagnosed with CD in childhood but who were asymptomatic as adults on a normal diet. 
The majority (48/61) showed different degrees of villous atrophy (silent CD) while 13 had 
no detectable atrophy (latent CD). Latent patients did not differ significantly from the 7 
control patients on a gluten-free diet, but did have CD-specific serum antibodies. However, 
this was not free of risk as 2 latent patients relapsed clinically and histologically on follow-
up. The use of enzyme supplementation would be recommended in cases of silent CD as 
otherwise risks of malignancy are raised, among other conditions. There is a wide range of 
symptoms and enteropathy caused by gluten (Picarelli et al., 1996). 
Finally, mention should be made of the status of first degree relatives of patients with CD. 
The finding that 82.3% do not have CD (Biagi et al., 2008) is in keeping with general 
experience. However, it is likely that many of these individuals will have some intolerance, 
in keeping with their partial enzyme deficiency (Cornell & Rolles, 1978) and therefore could 
be in the need of enzyme supplementation whilst on a normal or low gluten diet. 
9. Conclusions 
- Whether you agree with an enzyme deficiency in CD or simply believe that gliadin 
and certain other cereal proteins are difficult to digest down to non-toxic small 
peptides, enzyme therapy is an obvious answer to this problem. In our opinion it is 
the most useful advance in patient management since the gluten-free diet and 
deserves funding for further research. It could turn out to be a way of reversing 
damage to the small intestine caused by small amounts of gluten over extended 
periods of time. 
- A significant proportion of patients with CD show minimal symptoms despite 
challenge with gluten and are in need of enzyme supplementation as a means of 
protecting them from intestinal damage. This applies particularly to those patients, who 
are regarded as having silent CD and therefore in need of early diagnosis and 
treatment. Otherwise, the consequences can be very serious (Maki&Collin, 1997). 
Measurement of antibodies to tissue transglutaminase (tTG) is presently the most 
reliable diagnostic test with follow-up by biopsy (Van Heel & West, 2006). Modern 
practice makes use of deamidated gliadin peptide assays. 
- The use of extracts of pig intestinal mucosa confirmed that they were helpful in 
reducing the severity of symptoms induced in patients with CD (Cornell et al, 2006). 
This was taken to mean that such extracts were able to supply an enzyme or enzymes 
that were deficient in these patients. The enzymes in pig mucosa that make up for this 
deficiency are likely to be prolidases or oligoiminopeptidases capable of hydrolysing N-
terminal peptide bonds associated with proline residues. Such residues are contained 
within motifs of amino acids that are associated with toxicity and are left intact after 
 
Enzyme Therapy for Coeliac Disease: Is it Ready for Prime Time? 
 
159 
digestion with remission coeliac mucosa. Examples of these motifs are PQQPY, QQPYP 
found in wheat, rye and barley (Mc Lachlan et al.2002). 
- The uses of enzymes from Carica papaya, especially caricain, seem to be effective in 
vitro tests. A highly purified caricain preparation has performed extremely well in these 
tests and has led to the setting up of a clinical trial to test the value of caricain in 
enzyme therapy (Cornell & Stelmasiak, 2011). 
- Enzyme therapy is expected to act as a safeguard and relieve those who suffer from 
CD from the worry of maintaining a strict gluten-free diet. Products of high potency 
should allow some latitude with oats, a very nutritious cereal, which is not part of a 
gluten-free diet in several countries. The immunotoxicity of oats has been shown to 
depend on the particular cultivar (Silano et al., 2002). Furthermore, it has been 
shown that there are three levels of antigenicity according to their reactivity to 
antibodies against the 33-mer peptide of an alpha-gliadin. High, medium and absent 
reactivity were observed, correlating with measured activation of T-lymphocytes 
from patients with CD and hence potential immunotoxicity. (Comino et al., 2011). 
Oat intolerance may be responsible for villous atrophy seen in patients who are 
eating oats but otherwise are adhering to a strict gluten-free diet (Arentz-Hansen et 
al., 2004).  
- Although it is generally recognised that the function of HLA molecules is to present 
small peptides to T-cells, there is not a strong argument that HLA DQ2/DQ8 are 
primary causes of CD since a large proportion 25-30% of the Caucasian population also 
have this typing and do not have CD (Sollid, 2002). Instead, it is more reasonable to say 
HLA DQ2/DQ8 are predisposing factors and that the etiology is another genetic defect 
that manifests as an enzyme deficiency. Specific deamidation of a glutamine residue 
results in enhanced binding to those molecules and is important in the ensuing 
immunological reactions, but this probably only happens with peptides that have 
resisted digestion. 
- CD has a wide spectrum of clinical presentation and mucosal damage. Furthermore it is 
spread widely throughout the world with it now being recognised in parts of the Orient 
(Jiang et al., 2009). It could now be regarded as a systemic disease because of its effect 
on the various organs of the body. Another aspect of the deleterious effect of gluten is 
the likely, but not always proven, effect in other disorders such as schizophrenia, 
autism, irritable bowel syndrome and other situations where individuals do not tolerate 
gluten (the so-called non-coeliac gluten intolerance). 
- At the molecular level, there has been much progress in our understanding of those 
parts of the gliadin molecule that are the cause of further reactions that damage the 
small intestinal mucosa. Two regions of the A-gliadin molecule that remain undigested 
by remission coeliac mucosa are peptides from residues 12-19 and 77-84 and the 
problems seem to center around motifs associated with toxicity such as PSQQ, QQQP 
and QQPY. It should be noted that QQPYP and PQQPY are present in all three coeliac-
toxic cereals – wheat, rye and barley (McLachlan et al., 2002). 
- There appears to be a great need for enzyme therapy as a form of management in CD. It 
will reduce the worry connected with the necessity of keeping to a strict gluten-free 
diet, particularly when the food has been prepared outside the home or where 
contamination by wheat, rye or barley products is a possibility. By the use of a natural 
enzyme from the papaya plant, this should be able to be accomplished safely. However, 
clinical trials will be the arbiter of this project.  
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- The availability of new, highly sensitive and specific serological tests has led to the    
realization that CD is the most common food intolerance in the world (Accomando & 
Cataldo, 2004). We have always been aware of the need to understand the mechanisms 
that operate in this disease and resulting from these studies was the investigation of 
animal and plant enzymes as a form of therapy (Cornell & Stelmasiak, 2009). Coupled 
with this advance is the need for diagnosis of CD at an early age, making enzyme 
therapy an important lifetime management program. We think enzyme therapy is 
ready for “prime time”. 
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